[ad_1] Alembic Pharmaceuticals Limited has announced that it has received final USFDA approval for its Abbreviated New Drug Application (ANDA) for Nifedipine Extended-Release Tablets USP, 30 mg, 60 mg and 90 mg. USFDA approved ANDA therapeutically approved by Pfizer Inc. equivalent to the company’s Procardia XL Extended-Release tablets, 30 mg, 60 mg and 90 mg. … Read more
[ad_1] BAUDET, Minn.–(BUSINESS WIRE)–ANI Pharmaceuticals, Inc. (ANI or Company) (Nasdaq: ANIP) announced today that it has received Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (FDA) for trimethoprim tablets USP, 100 mg. ANI’s Trimethoprim tablets are the generic version of the Reference List Drug (RLD) of the same brand name. … Read more
[ad_1] Cambridge, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of oral, small molecule protease inhibitors, today announced positive Phase 1 data for an orally disintegrating tablet (ODT). Its lead compound is the formula for sebetralstat. Sebetralstat is currently being developed as a … Read more